Unmet Needs and Key Takeaways: ECHO Clinical Trial

Opinion
Video

Medical experts evaluate unmet needs, key insights from the Phase 3 ECHO trial, and potential obstacles in integrating the findings into existing treatment protocols.

  1. What is your standard of care (SOC) in this patient population?
  2. How does this regimen (BTKi+BR) compare in efficacy and safety to your SOC?
Recent Videos
3 experts in this video
Related Content
The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

FDA Issues CRL for Tabelecleucel in EBV+ Lymphoproliferative Disease

Roman Fabbricatore
January 17th 2025
Article

The CRL did not identify any deficiencies related to the manufacturing, efficacy, or safety outlined in the BLA, and no new clinical trials were requested.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MBA, MSc
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

FDA Approves Acalabrutinib Combo in Previously Untreated MCL

Tim Cortese;Ariana Pelosci
January 16th 2025
Article

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

3 Things You Should Know About Immunotherapy in DLBCL

3 Things You Should Know About Immunotherapy in DLBCL

Matthew A. Lunning, MD;Grzegorz S. Nowakowski, MD
December 19th 2024
Article

Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Positive ORR Yielded by Iopofosine I 131 in R/R Waldenström Macroglobulinemia

Ashley Chan
December 13th 2024
Article

Results from the CLOVER WaM trial saw a clinical benefit rate of 98.2% in patients with Waldenström Macroglobulinemia treated with Iopofosine I 131.